In a move to expand its native advertising business, Time Inc. has promoted Chris Schraft to president of content sales and agency development of The Foundry, its branded content studio. 'The NewYorker' has hired Dan Oshinsky as its first director of newsletters.
NYS Entity Status
NYS Filing Date
APRIL 16, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - A PLUS SALES & MARKETING INC.
AROUND THE WEB
- Time Inc Taps Schraft To Head Foundry's Content Sales, 'New Yorker' Hires First Newsletter Director
Thursday Jul 13, 2017
- Time Inc. Moves Into Social Video, Targets GenZ And Millennials With 'The Pretty'
Tuesday Jun 20, 2017
Eager to capture the attention of 16- to-35-year-old beauty enthusiasts, Time Inc. has launched "The Pretty," a new social video brand. What's notable is the all-video approach that offers how-tos,hacks, product information, and entertainment, plus the plan to target both GenZ -- starting at around age 16 -- in addition to Millennials.
- Amazon stopped Whole Foods from seeking a bidding war
By Reuters - Friday Jul 7, 2017
Amazon.com Inc told Whole Foods Market Inc it would not engage in a sale process for the U.S. grocer that involved other bidders, a regulatory filing showed on Friday, shedding new light on the $13.7 billion acquisition. The previously undisclosed details on the negotiations show how Amazon used its deep pockets and brand as leverage […]
- Abbvie’s hep C drug pricing threatens Gilead’s dominance
By Max Nisen - Tuesday Aug 8, 2017
Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.
- Email A Distant Fourth In Back-To-School Sales
Thursday Aug 3, 2017
It's already August. Brands have only a few weeks to get out their back-to-school sales.